Latest
industry research report on: Asia-Pacific Anti-hypertensive
Therapeutics Market | Industry Size, Share, Research, Reviews, Analysis,
Strategies, Demand, Growth, Segmentation, Parameters, Forecasts
Hypertension
is a serious and common medical condition characterized by elevated
blood pressure. It is commonly seen in the aging population, and in
people with sedentary lifestyles and obesity. As one of the most
significant preventable causes of death worldwide, early diagnosis of
the condition is crucial to improve health outcomes. Hypertension is the
key risk factor for stroke; according to the National Stroke
Association (NSA), two-thirds of patients who suffer a stroke have
hypertension.
Complete Report Details @ http://www.marketresearchreports.biz/analysis/903617
Hypertension
itself does not manifest any symptoms, but direct damage can occur to
various organs due to high blood pressure. In cases of hypertensive
emergency (where blood pressure is higher than 180/110mmHg) patients
have reported headaches, breathlessness or malaise due to heart failure
and kidney failure. Whether symptomatic or asymptomatic, hypertension
requires attention and appropriate changes in lifestyle or medical
treatment
The
marketed products landscape for hypertension comprises a wide range of
treatment options, which includes angiotensin converting enzyme
inhibitors, angiotensin receptor blockers, calcium channel blockers,
beta blockers, renin inhibitors, and diuretics. These are used both as
monotherapy and combination therapy (including fixed-dose combinations),
and the proportion of patients treated using the various therapy
approaches varies from country to country.
The
high prevalence of the disease is a substantial contributor to
healthcare costs and is a major cause of morbidity. However, awareness
of hypertension is low among physicians, patients, and the public,
leading to a high level of undiagnosed and untreated cases.
Download Sample copy of this Report at : http://www.marketresearchreports.biz/sample/sample/903617
Scope
- The Asia-Pacific antihypertensive market will be valued at $27 billion in 2022, growing from $19.1 billion in 2015 at a CAGR of 5.1%. Hypertension prevalence is a prominent contributor to market size in the assessed countries. The market is mostly dominated by generics, and there are only a few patented products.
- Will generics continue to dominate treatment?
- How do the elderly populations and their associated risk factors affect prevalence?
- What effect will the patent expirations of currently branded therapies have on market value?
The
current anti-hypertensive therapeutics pipeline is weak, comprising 112
molecules in various stages of development, dominated by small
molecules.
- Which molecular targets appear most frequently in the pipeline?
- Is there potential for the pipeline to address unmet needs within the anti-hypertensive market?
Analysis of clinical trials since 2006 identified that anti-hypertensive products have a high rate of attrition.
- How do failure rates vary by product stage of development, molecule type, and mechanism of action?
- How do other factors such as average trial duration and trial size influence the costs and risks associated with product development?
The
market forecasts indicate that Japan will contribute the most to the
Asia-Pacific market value, due to the high annual cost of therapy.
Growth in market size is projected to vary considerably across the five
assessed markets.
- How will the annual cost of therapy and market size vary between the five Asia-Pacific markets?
- How could changes in risk factors such as aging population, metabolic disorders and high salt intake influence the market?
- Various drivers and barriers will influence the market over the forecast period.
- What are the barriers that limit the uptake of premium-priced therapeutics in the assessed countries?
- Which factors are most likely to drive the market in these countries?
Reasons to buy
This report will allow you to
- Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.
- Visualize the composition of the anti-hypertensive market in terms of the dominant therapies, and their clinical and commercial standing. Unmet needs are highlighted to allow a competitive understanding of gaps in the market.
- Analyze the anti-hypertensive pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target.
- Consider market opportunities and potential risks by examining trends in hypertension clinical trial size, duration, and failure rate by stage of development, molecule type, and mechanism of action.
- Predict anti-hypertensive market growth in the five Asia-Pacific markets with epidemiological and annual cost of therapy forecasts across India, China, Australia, South Korea and Japan. The forecasts will provide an understanding of how epidemiology trends, new drug entries, and patent expirations will influence market value.
- Identify commercial opportunities in the anti-hypertensive deals landscape by analyzing trends in licensing and co-development deals
About us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save time
and money for our clients. We are a one stop solution for all your
research needs, our main offerings are syndicated research reports,
custom research, subscription access and consulting services. We serve
all sizes and types of companies spanning across various industries.
Contact
Mr. Nachiket
State Tower
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-621-2074
No comments:
Post a Comment